Paediatric Endocrinology Watch Time: 20 mins

touchCONGRESS Expert Interviews Leading the conversation in paediatric endocrinology

Watch a series of internationally renowned clinical specialists discuss the clinical landscape for severe primary IGF-1 deficiency (SPIGFD), including data from the European Society for Paediatric Endocrinology (ESPE) 2018 Congress in Athens, Greece, 27–29 September 2018.

  • Expert Interviews
Leave Feedback
Prof. Martin Savage
Watch Time: 12:33
Barts and the London School of Medicine and Dentistry, London, UK

Prof. Martin Savage, Professor Emeritus in Paediatric Endocrinology at the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry in London, UK, provides his expert insight into key data presented at ESPE 2018 and what they may mean for optimizing clinical outcomes for patients with severe primary IGF-1 disorder (SPIGFD).

 
Leave Feedback
Interview Questions

In this interview, Martin Savage answers the following questions:

  • How often do you diagnose SPIGFD in your region, and is it widely acknowledged as a potential diagnosis in children with short stature?
  • Are physicians in your region aware of the different treatment needs for growth hormone deficiency (GHD) and SPIGFD?
  • How early are GHD and SPIGFD generally diagnosed in your region, and why is it important to diagnose and treat these conditions early in life?
  • How might the data presented at ESPE 2018 add to clinical practice regarding SPIGFD in your region?
  • How valuable are real-world data from registries and do they reflect your clinical experience?
About Prof. Martin Savage

Prof. Martin Savage is a Professor Emeritus in Paediatric Endocrinology at the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry in London. He was head of the Paediatric Endocrine Unit at both universities from 1982 to 2007. He is a clinician with wide experience and has clinical and research interests in the field of growth disorders, specifically those with abnormalities in the growth hormone-IGF-1 axis. His main research field has been the phenotype:genotype relationships of GH-IGF-1 axis defects. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.

Professor Savage’s other clinical interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. Professor Savage has lectured in more than 50 countries worldwide and has published over 420 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology. He continues to see patients and lectures both nationally and internationally.

Prof. Martin Savage discloses:  Consultancy agreements with Sandoz UK and Global, Merck KGaA Darmstadt, OPKO, Genexine/Handok, Novartis and Springer IME.  Speaker honoraria from Novo Nordisk and Pfizer.

Prof. Stefano Cianfarani
Watch Time: 07:04
Bambino Gesù Children’s Hospital in Rome, Italy

Prof. Stefano Cianfarani, Associate Professor of Paediatrics and Chief of the Molecular Endocrinology Unit, ‘Bambino Gesù’ Children’s Hospital, Rome, Italy, provides his expert insight into key data presented at ESPE 2018 and what they may mean for optimizing clinical outcomes for patients with severe primary IGF-1 disorder (SPIGFD).

 
 
Leave Feedback
Interview Questions

In this interview, Stefano Cianfarani answers the following questions:

  • How often do you diagnose SPIGFD in your region, and is it widely acknowledged as a potential diagnosis in children with short stature?
  • Are physicians in your region aware of the different treatment needs for growth hormone deficiency (GHD) and SPIGFD?
  • How early are GHD and SPIGFD generally diagnosed in your region, and why is it important to diagnose and treat these conditions early in life?
  • How might the data presented at ESPE 2018 add to clinical practice regarding SPIGFD in your region?
  • How valuable are real-world data from registries and do they reflect your clinical experience?
About Prof. Stefano Cianfarani

Prof. Stefano Cianfarani is Associate Professor of Paediatrics and Chief of the Paediatric Endocrinology Centre at the ‘Tor Vergata’ University, and Chief of the Diabetology Unit at the ‘Bambino Gesù’ Children’s Hospital in Rome, Italy. He is also Visiting Professor at the Department of Women’s and Children’s Health at the Karolinska Institute, Stockholm, Sweden. He trained in paediatric endocrinology at the ‘La Sapienza’ and ‘Tor Vergata’ Universities of Rome and refined his training at St. Bartholomew’s Hospital, London, UK.

Professor Cianfarani is active in both clinical and laboratory-based research. From 2004 to 2010, he was chairman of the Clinical Practice Committee and a member of the Programme Organizing Committee and Council for the European Society for Paediatric Endocrinology (ESPE).

Prof. Stefano Cianfarani reports no conflicts of interest.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Watch a series of internationally renowned clinical specialists discuss the clinical landscape for severe primary IGF-1 deficiency (SPIGFD), including data from the European Society for Paediatric Endocrinology (ESPE) 2018 Congress in Athens, Greece, 27–29 September 2018.

The potential implications of these data for optimizing clinical outcomes for patients with SPIGFD are explored from both global and regional perspectives.

The information in this activity is intended for European endocrinologists, nurses, and other healthcare professionals involved in the treatment of patients with short stature.

Learning Objectives

After watching these touchCONGRESS Expert Interviews, you should be better prepared to:

  • Share your increased awareness and understanding of SPIGFD
  • Contribute to the optimization of diagnosis in paediatric growth hormone insensitivity syndromes
  • Demonstrate increased familiarity and confidence with early treatment of SPIGFD
  • Drive improved patient outcomes through sharing of best practice.

This content is intended only for healthcare professionals outside of the US.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS Expert Interviews on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72